VZV IgG Antibody Testing Services

Varicella-Zoster Virus (VZV) is a highly contagious human herpesvirus. Primary infection usually causes chickenpox (varicella), after which the virus establishes latency in the host's sensory ganglia. When host immunity declines, the virus can reactivate and cause shingles (herpes zoster).

In biomedical basic research and epidemiological investigations, defining the host's immune status against VZV is crucial. Following natural infection or vaccination, the host's immune system produces specific Immunoglobulin G (IgG). Therefore, the VZV IgG antibody is a core serological biomarker used to evaluate whether a host has been previously infected with VZV and/or has received a VZV vaccine. Accurate qualitative analysis of VZV IgG provides critical data support for building population immunity models, assessing vaccine durability, and investigating the mechanisms of viral latency and reactivation.

Our Services

We provide standardized VZV serological analysis services for research teams and biopharmaceutical companies. The core objective of this service is the high-precision qualitative detection of VZV-specific IgG antibodies in research serum samples.

• Core Technology: Chemiluminescence Immunoassay (CLIA)
  We utilize an advanced CLIA platform to perform VZV IgG testing. Compared to traditional ELISA, CLIA uses luminescent substrates instead of chromogenic ones, offering exceptionally high detection sensitivity, a broader dynamic linear range, and outstanding lot-to-lot stability. This technology can acutely capture trace specific antibody signals in samples, effectively reducing the false-negative rate in research experiments and ensuring high data reliability.

Our Advantages

• High-Sensitivity CLIA Platform: Relying on automated chemiluminescence analyzers, we minimize human error, enabling the rapid and precise qualitative screening of high-throughput research samples.
• Strict Research Quality Control: We establish rigorous negative/positive controls and quality control baselines to ensure objective and accurate result interpretation, delivering data that fully meets the publication standards of high-tier academic journals.
• Customized Project Support: Whether it's a small-scale in vitro model validation or a large-scale epidemiological cohort screening, we offer flexible, efficient project scheduling and data delivery services.

Sample Requirements

To guarantee the absolute rigor of research data on our CLIA platform, please carefully read and adhere to the following sample preparation and shipping guidelines before submission:

• Sample Type: Serum.
• Sample Volume: A minimum of 0.5 mL of serum is required per test.
• Aliquot & Transfer Guidelines: If using standard blood collection tubes other than gel-separator tubes, you must transfer the separated serum supernatant into a clean plastic transport tube after centrifugation prior to shipping.
• Cold Chain & Freeze-Thaw Precautions: Do not freeze gel-separator tubes directly. If samples require frozen storage or dry ice transport, you must pour off (or pipette) the serum into a new cryovial before freezing.
• Rejection Criteria: Any sample exhibiting obvious hemolysis, severe lipemia, or heavy bacterial contamination will cause severe matrix interference with the luminescent signal. To uphold the integrity of your research data, such samples will be immediately rejected during laboratory accessioning. Please strictly control quality during sample collection.

In the realms of VZV epidemiological surveillance and vaccine R&D, precise and reliable serological data is the core driver of scientific progress. We look forward to safeguarding your high-level research with our highly efficient CLIA testing platform and stringent quality controls. Contact our technical experts today to discuss your VZV sample analysis needs, and let's work together to accelerate your research translation!